Hemostatic abnormalities were examined in 55 patients during maintenance hemodialysis (HD). Before HD, plasma protein C and protein S antigens were almost within the normal range, while plasma thrombin-antithrombin III complex (TAT III) and plasmin-plasmin inhibitor complex (PPIC) levels in HD patients were increased slightly, and plasminogen activator inhibitor 1 level was significantly increased, compared to that in normal volunteers. Plasma activated protein C (APC) and protein C inhibitor (PCI) complex and APC &alpha;1 antitrypsin (&alpha;1AT) complex were not detected in normal volunteers; however, plasma APC-PCI complex was increased in 36 of the patients and plasma APC-&alpha;1AT complex was increased in 25 patients. Plasma PCI levels in these patients before HD were significantly decreased. Plasma TAT, PPIC, and tissue type plasminogen activator levels were significantly higher before HD than after 1 hour HD and at the end of HD, while the changes in plasma protein C antigen, protein S antigen, PCI antigen, APC-PCI complex, and APC-&alpha;1AT complex were not significant after 1 hour of HD or at the end of HD compared to levels before HD. Plasma PCI levels were correlated with APC-PCI complex, suggesting that decreased PCI levels might be caused by the activation of protein C.
Although the survival of patients with chronic renal failure has been increased by maintenance hemodialysis (HD), vascular and hemostatic complications are now a major problem in these patients. Pooled data from hemodialysis centers in the United States have revealed a remarkably high mortality rate from cardiovascular disease in long-term HD patients (1) . Data collected from the European Dialysis and Transplant Association show that more than 60% of deaths in such patients were due to cardiovascular disease (2) . The incidence of hypertension and metabolic disturbances are higher in HD patients. Further, alterations in hemostasis, an important cardiovascular risk factor, have been reported in these patients (3) . In recent years a clear association has been established between thromboembolic disease and hereditary deficiency of protein C (4) and protein S (5) . Protein C, after its activation on endothelial cells by the throm-bin-thrombomodulin complex (6) , selectively degrades coagulation factors Va and Villa. Thrombin-antithrombin complex (TAT) (7) , and plasmin-plasmin inhibitor complex (PPIC) (8) are sensitive markers of thrombosis or fibrinolysis. They have also been shown to be useful in the diagnosis of disseminated intravascular coagulation (DIC) and thrombotic diseases. Although reduced protein C levels have been reported in patients with thrombotic diseases (9), the reduction is not significant, nor is it specific for such diseases. Changes in levels of complexes of activated protein C (APC) and its inhibitors have now been shown in thrombotic disorders (10) and plasma APC has also been detected directly ( 11, 12) . In this study, we measured plasma levels of TAT, PPIC, protein C inhibitor (PCI), APC-PCI complex, and APCa 1-antitrypsin (ex 1 A T) complex in patients on maintenance HD to elucidate hemostatic abnormalities.
MATERIAL AND METHODS
Hemostatic abnormalities were examined in 55 patients (38 males, 17 females; age, 30-77 years; mean age, 53.3 ± 11.0 years) on maintenance HD. Twenty healthy volunteers were also examined. The period on HD was 0.5 to 21.8 years (mean, 8.7 ± 4.8 years). The primary disease in all patients was glomerulonephritis. None of the patients had severe liver dysfunction, acute thrombosis, or vascular complications. Each patient received HD for 4 to 5 hours, three times a week; this was carried out with a hollow-fiber dialyzer (surface area, 1.0-2.0 m2). For each dialysis, an average of 5,000 U heparin was given. Blood samples were collected immediately before HD, after 1 hour of HD, and at end of the HD treatment. Whole blood was anticoagulated with a solution of 9 volumes of blood to 1 volume of 3.8% trisodium citrate solution. Plasma protein C and protein S antigens were measured by enzyme-linked immunosorbent assays (ELISA) using antiprotein C polyclonal antibody (Dakopatts, Hagersten, Denmark) and antiprotein S polyclonal antibody (Dakopatts), respectively. Plasma TAT, PPIC, tissue type plasminogen activator (TPA), and plasminogen activator inhibitor-I (PAI-1 ) levels were determined using the following kits; Enzygnost-TAT (Behringwerke AG, Marburg, Germany) (13) , PICtest (Teijin, Tokyo, Japan) (8) , TPA EIA kit (Fujirebio, Ltd, Tokyo, Japan), and Imulyze PAI-1 (Biopool, Umea, Sweden), respectively. PCI and APC were purified and prepared as described earlier (14, 15) . Antiserum against purified PCI was raised by immunizing rabbits, and anti-PCI rabbit immunoglobulin was isolated from the serum. The PCI antigen was measured by ELISA using an anti-PCI polyclonal antibody (16) . An APC complex with PCI was formed by a 2-hour incubation period in the presence of 10 U/mL of heparin at 37°C. The complex was purified by gel filtration on an ACA 44 (Ultrogel ACA) column (0.9 x 60 cm). An APC complex with cx 1 AT was formed by 2-hour incubation at 37°C; this complex was purified in the same manner. Plasma APC-PCI complex and APC-a I AT complex levels were measured by sandwich ELISA described below. Patient plasma was precipitated with BaC12, and the precipitate was used as the test sample in the assays. Briefly, microplates were coated with anti-PCI monoclonal antibody or anti-a 1 AT polyclonal antibody (Organon Teknika Co. Durham, NC, U.S.A.), and test samples were incubated in the microplates; APC complexes with their inhibitor were detected with a peroxidase-labeled monoclonal antiprotein C antibody. Reference curves were constructed with known amounts of in vitro preformed complexes. The detection limits of the assay for the APC-PCI complex and the APC-a 1 AT complex in plasma were 0.4 ng/mL and 3.4 ng/mL, respectively. The reproducibility (coefficient of variation [CV]) of the APC-PCI complex assay was 5.2% and the CV of the APC-a I AT complex was 6.5%. The protein C monoclonal antibody bound the light chain of protein C and did not inhibit protein C activity. The anti-PCI monoclonal antibody did not bind the heparin binding site and did not inhibit PCI activity, although it bound the PCI and the APC-PCI complexes (17) . Statistical analysis was performed using the Wilcoxon test; p < .05 was considered significant.
RESULTS
Immediately before HD, plasma TAT and PIC levels in the patients were increased slightly, and plasma PAI-1 I levels were significantly increased compared to levels in normal volunteers. Plasma protein C, protein S, and TPA antigen levels were almost within the normal range (Table 1 ). Plasma TAT, PIC, and TPA antigen levels at 1 hour after HD and at the end of HD were significantly higher than levels before HD, while the plasma PAI-1 antigen level at the end of HD was significantly decreased compared to that before HD. Plasma protein C and protein S antigens were slightly increased at 1 hour after HD and at the end of HD, compared to levels before HD ( Table 2 ). Plasma APC-PCI complex and APCa 1 AT complex were not detected in normal volunteers; however, before HD, plasma APC-PCI complex (4.65 ± 4.83 ng/mL) was increased in 36 patients and plasma APC-a 1 AT complex (3.00 ± 3.92 ng/mL) was increased in 25 patients. Plasma PCI levels in the HD patients before HD (56.9 ± 20.3%), however, were significantly decreased (p < .01). Plasma APC-PCI complex (5.35 ± 4.98 ng/mL and 5.91 ± 5.64 ng/mL, respectively) and APC-alAT complex (3.68 ± 4.68 ng/mL and 4.13 ± 5.60 ng/mL, respectively) after 1-hour HD and at the end of HD were slightly increased compared to values before HD (Fig. 1) . The plasma PCI level after 1-hour HD (65.8 + 34.9%) was slightly increased compared to the level before HD, and the level at the end of HD (61.8 ± 20.3%) was slightly decreased compared to the level I hour after HD (Fig. 2 ). Decreased PCI levels before HD were not correlated with age, years on HD, or plasma levels of TAT, PIC, protein C, protein S, TPA, or PAI-1. Only the plasma level of the APC-PCI complex (r = 0.307, p < .05) correlated with the plasma PCI level before HD (Table 3) . , .
DISCUSSION z
The protein C pathway is important in anticoagulation (18) , and deficiencies of protein C have been shown to be (19) . Protein C can be rapidly activated to form APC by thrombin (20) in the presence of thrombomodulin (21) . The presence of an APC inhibitor in human plasma was first described in 1980 (22) and the first heparin-dependent inhibitor of APC, termed PCI, was later purified and characterized (14) . Subsequently, a second, heparin-independent inhibitor of APC, alAT, was reported in human plasma (23). Further, it has been reported that plasmin inhibitor and a2 macroglobulin inactivate APC (24) . The increases in plasma TAT, PIC, PAI-1, APC-PCI complex, and APC-a 1 AT complex levels in HD patients suggests that these patients were in a hypercoagulable and hyperfibrinolytic state; however, the fibrinolytic activity may be inhibited by Pay-1. The plasma PCI levels were also significantly decreased in these patients. However, neither the APC-PCI complex nor the APC-a 1 AT complex were detected in the plasma of normal volunteers, and plasma APC-PCI complex and APC-a 1 AT complex levels were increased in many of the patients on HD. These findings suggested that protein C was slightly activated in these patients and that since the plasma PCI level was significantly decreased, then PCI and a 1 AT were the major inhibitors of APC. Increases in plasma APC-PCI and APC-a 1 AT complex levels and decreases in plasma PCI levels have been reported in DIC patients (25, 26 ), suggesting that PCI and a 1 AT are major inhibitors of APC in DIC. However, only the APC-PCI complex, and not the APC-cx 1 AT complex was increased in patients with pulmonary embolism, suggesting that PCI may be the major inhibitor of APC in conditions where there is moderate activation of protein C and normal plasma PCI levels. In such a state, measurement of the APC complex and its inhibitor might be the most useful method for detecting protein C activation, although plasma APC has been detected directly ( 10, 11 ) .
It is possible that the increase in PIC during HD might have been caused by the release of TPA from endothelial cells. However, the increases in plasma TAT levels and the lack of change in plasma levels of APC-APC inhibitor complex in HD patients suggest that, in the presence of heparin, thrombin is immediately inhibited by anti- TABLE 
Correlation between PCI and various parameters
PCI, protein C inhibitor; APC, activated protein C; aIAT, alantitrypsin. (See Table I for remaining definitions.) thrombin III (AT III) and plasma protein C is not sufficiently activated. As thrombin is immediately inhibited by AT III and TPA is released from endothelial cells during HD, we consider that a hyperfibrinolytic state exists during HD. The increased plasma APC-PCI complex and PAI-1 levels suggest a hypercoagulable state before HD. Protein C inhibitor is an important inhibitor not only for APC but also for plasminogen activator. In conclusion, it appears that decreased plasma PCI levels might be due to the activation of protein C, but not to hyperfibrinolysis, since plasma PCI levels before HD were correlated only with levels of plasma APC-PCI complex.
